Dr. Karine Kleinhaus, Divisional Vice President for Pluristem a clinical-stage biotechnology company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases joins eHealth Radio and the Female Health and Pregnancy Channels to discuss the cure to preeclampsia.
Listen to interview with host Eric Michaels & guest Dr. Karine Kleinhaus discuss the following:
- It has been announced that May is National Preeclampsia Month? What exactly is preeclampsia?
- Has there been any new developments in regards to the condition?
- Placental cell therapy being touted as a new approach to preeclampsia? If so, what is it and how does it work?
- When will see this in patients?
Karine Kleinhaus, M.D., MPH, is the Divisional Vice President at North America at Pluristem Therapeutics. Prior to her joining Pluristem Therapeutics, she was an assistant professor in the departments of psychiatry and obstetrics and gynecology at the NYU School of Medicine. At NYU, Dr. Kleinhaus conducted medical research funded under a multi-year NIH grant. She published more than 25 papers in leading peer-reviewed journals such as the Annals of the New York Academy of Science, American Journal of Medical Genetics, and American Journal of Epidemiology.
Prior to that Dr. Kleinhaus practiced obstetrics and then completed two fellowships at Columbia University. Dr. Kleinhaus received her medical degree from Tel Aviv University, earned a Master of Public Health from Columbia’s Mailman School of Public Health, and a bachelor’s degree, cum laude, from Princeton University.
Web Site: www.pluristem.com